Researchers at the University of Virginia, in collaboration with Manchester, UK-based APIS Assay Technologies Ltd., have discovered Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase is detectable in non-invasive prostate cancer patient samples.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
